LYRA, US55234L2043

Lyra Therapeutics stock trades OTC at USD 0.15 after delisting

Published on 10/04/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyra Therapeutics stock was last at USD 0.15 on October 2, 2026, with a USD 0.3 million market cap. FY2025 revenue was USD 398,000 and net loss USD 28.92 million.

LYRA, US55234L2043, Illustration mit AI erstellt.

Lyra Therapeutics stock (ISIN US55234L2043) was last at USD 0.15 on OTC Markets on October 2, 2026 at 4:00 p.m. ET, leaving the company with a USD 0.3 million market capitalization. The OTC listing follows the suspension of Nasdaq trading and a delisting process described in the company's recent corporate history.

OTC trading follows Nasdaq suspension

Investing.com identifies Lyra as an OTC Markets security under ticker LYRA and lists the input ISIN US55234L2043. Its October 4, 2026 quote page shows USD 0.15, a USD 0.010 to USD 8.748 52-week range and a USD 266,230 market capitalization.

EdgeChat reports that Nasdaq suspended Lyra's trading on March 17, 2026 after the company suspended development of LYR-210 in January. The same account says Nasdaq had begun delisting procedures in March, making the OTC quotation a materially different market setting from Lyra's former Nasdaq listing.

Revenue fell sharply in FY2025

Fundamentals Hub, using company filing data, reports FY2025 revenue of USD 398,000 versus USD 1.53 million in FY2024. That represents a 74.0 percent year-over-year decline and leaves revenue far below the level reported two fiscal years earlier.

The same FY2025 data show a net loss of USD 28.92 million, compared with a USD 93.44 million loss in FY2024. Cash and equivalents stood at USD 15.89 million at December 31, 2025, while cash from operations was negative USD 28.86 million for the year.

Lyra stock remains highly distressed

Lyra's investor-relations page describes a clinical-stage biotechnology company developing long-acting anti-inflammatory nasal inserts for chronic rhinosinusitis, including LYR-210 and LYR-220. The products were designed to deliver six months of therapy through a single in-office administration, according to the Lyra Therapeutics investor-relations page.

For investors, the key distinction is between the company's therapeutic platform and its trading status. The October 2 price of USD 0.15 stands 98.3 percent below the 52-week high of USD 8.748, while the USD 0.3 million market capitalization reflects a company still carrying substantial operating losses and a sharply reduced commercial profile.